BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

An Embarassed GlaxoSmithKline (GSK) Spanks Two Key Executives


8/22/2010 10:42:45 AM

Pharmalot -- File this under ‘what were they thinking?’ Two years ago, Glaxo ponied up $720 million to buy Sirtris Pharmaceuticals, which is famous for trying to develop medicines based on a chemical in red wine known as resveratol. This generated intense interest because it may have an effect on aging - you know, the fountain of youth (back story). The science has since been questioned, but meanwhile, two key Sirtris execs assumed important roles within Glaxo’s hiearchy - Michelle Dipp became senior vp of Glaxo’s Center of Excellence for External Drug Discovery and Christoph Westphal now heads SR One, a venture capital unit.

Read at Pharmalot

Pharmalot
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES